3,4,5-trichlorophenol is a synthetic organic compound classified as a chlorophenol. It is a colorless to light yellow solid at room temperature. It is used as an intermediate in the production of other chemicals, such as herbicides and pesticides. 3,4,5-trichlorophenol is also found in the environment as a result of industrial pollution. It is a toxic compound, and its exposure can cause a variety of health problems, including skin and eye irritation, liver damage, and cancer. Research on 3,4,5-trichlorophenol focuses on its environmental fate, toxicity, and remediation. It is studied to understand its potential risks to human health and the environment, and to develop methods for its removal from contaminated sites.'
ID Source | ID |
---|---|
PubMed CID | 11859 |
CHEMBL ID | 1484480 |
SCHEMBL ID | 330705 |
MeSH ID | M0528201 |
Synonym |
---|
2jf54ege7o , |
unii-2jf54ege7o |
3,4,5-trichlorophenol |
phenol, 3,4,5-trichloro- |
nsc-243667 |
wln: qr cg dg eg |
nsc243667 |
609-19-8 |
3,5-trichlorophenol |
NCGC00091866-01 |
hsdb 6292 |
ccris 6110 |
einecs 210-183-0 |
nsc 243667 |
inchi=1/c6h3cl3o/c7-4-1-3(10)2-5(8)6(4)9/h1-2,10h |
gbnhebqxjvdxsw-uhfffaoysa- |
smr001307309 |
MLS002302993 , |
A832955 |
3,4,5-tris(chloranyl)phenol |
NCGC00091866-02 |
AKOS006275453 |
HMS3039M04 |
NCGC00257742-01 |
tox21_200188 |
dtxcid106212 |
cas-609-19-8 |
dtxsid4026212 , |
FT-0648040 |
3,4,5-trichlorophenol [hsdb] |
trichlorophenol, 3,4,5- |
CHEMBL1484480 |
SCHEMBL330705 |
cid_11859 |
bdbm91350 |
phenol, 3,4,5-trichloro-; 3,4,5-trichlorophenol; nsc 243667 |
3,4,5-trichlorophenol 10 microg/ml in isooctane |
3,4,5-trichlorophenol 100 microg/ml in acetonitrile |
3,4,5-trichlorphenol |
DS-5129 |
F16449 |
mfcd00130143 |
AMY28145 |
Q27254825 |
A928575 |
CS-0157727 |
SY117365 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, HADH2 protein | Homo sapiens (human) | Potency | 39.8107 | 0.0251 | 20.2376 | 39.8107 | AID886 |
Chain B, HADH2 protein | Homo sapiens (human) | Potency | 39.8107 | 0.0251 | 20.2376 | 39.8107 | AID886 |
interleukin 8 | Homo sapiens (human) | Potency | 74.9780 | 0.0473 | 49.4806 | 74.9780 | AID651758 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 12.5893 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 50.8464 | 3.1890 | 29.8841 | 59.4836 | AID1224846; AID1224894 |
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 26.9884 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
TDP1 protein | Homo sapiens (human) | Potency | 23.7246 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 26.0264 | 0.0007 | 14.5928 | 83.7951 | AID1259368; AID1259369; AID1259392 |
AR protein | Homo sapiens (human) | Potency | 34.2043 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID588515; AID588516; AID743035; AID743036; AID743042; AID743054; AID743063 |
PINK1 | Homo sapiens (human) | Potency | 14.1254 | 2.8184 | 18.8959 | 44.6684 | AID624263 |
estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 14.5624 | 0.0006 | 57.9133 | 22,387.1992 | AID1259378 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 63.8233 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224893 |
progesterone receptor | Homo sapiens (human) | Potency | 12.9787 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 18.1408 | 0.0002 | 14.3764 | 60.0339 | AID588533; AID720692 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 60.5883 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 34.7017 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531; AID588544; AID588546 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 34.4064 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 45.9737 | 0.3758 | 27.4851 | 61.6524 | AID588526; AID743217 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 29.0558 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 38.2738 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID1259383; AID588513; AID588514; AID743069; AID743075; AID743078; AID743079 |
Parkin | Homo sapiens (human) | Potency | 14.1254 | 0.8199 | 14.8306 | 44.6684 | AID624263 |
peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 40.1602 | 0.0010 | 24.5048 | 61.6448 | AID588534; AID743215 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 46.7752 | 0.0010 | 19.4141 | 70.9645 | AID743094; AID743191 |
IDH1 | Homo sapiens (human) | Potency | 29.0929 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 65.0478 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
activating transcription factor 6 | Homo sapiens (human) | Potency | 43.0651 | 0.1434 | 27.6121 | 59.8106 | AID1159516; AID1159519 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 58.4983 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 49.3018 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 11.2202 | 0.0018 | 15.6638 | 39.8107 | AID894 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 39.8107 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 15.1767 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
heat shock protein beta-1 | Homo sapiens (human) | Potency | 59.9063 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 16.4492 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID743202 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 35.4813 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
geminin | Homo sapiens (human) | Potency | 18.3564 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 12.5893 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 12.5893 | 0.0200 | 10.7869 | 31.6228 | AID912 |
Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 41.0424 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 32.6192 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID651743 |
Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 41.0424 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Alpha-synuclein | Homo sapiens (human) | Potency | 11.2202 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 13.3332 | 0.0266 | 22.4482 | 66.8242 | AID651802 |
Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 35.4813 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1.0000 | 12.2248 | 31.6228 | AID885 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
corticotropin-releasing hormone receptor 2 | Homo sapiens (human) | IC50 (µMol) | 14.5450 | 0.3680 | 7.0955 | 18.0000 | AID602180; AID651639 |
corticotropin releasing factor-binding protein | Homo sapiens (human) | IC50 (µMol) | 14.5450 | 0.3680 | 7.0955 | 18.0000 | AID602180; AID651639 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
corticotropin-releasing hormone receptor 2 | Homo sapiens (human) | EC50 (µMol) | 53.0000 | 1.1200 | 11.5617 | 36.8000 | AID602473 |
corticotropin releasing factor-binding protein | Homo sapiens (human) | EC50 (µMol) | 53.0000 | 1.1200 | 11.5617 | 36.8000 | AID602473 |
Pentachlorophenol 4-monooxygenase | Sphingobium chlorophenolicum | Kd | 500.0000 | 0.0500 | 3.7500 | 7.0000 | AID1799831 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1799831 | Spectroscopic Assay from Article 10.1021/bi300261p: \\Pentachlorophenol hydroxylase, a poorly functioning enzyme required for degradation of pentachlorophenol by Sphingobium chlorophenolicum.\\ | 2012 | Biochemistry, May-08, Volume: 51, Issue:18 | Pentachlorophenol hydroxylase, a poorly functioning enzyme required for degradation of pentachlorophenol by Sphingobium chlorophenolicum. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (25.00) | 29.6817 |
2010's | 5 (62.50) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.43) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |